UT Southwestern Medical Center Scientists’ Discovery Of Rare Gene Mutation … – BioNews Texas
By Dr. Matthew Watson
 BioNews Texas | UT Southwestern Medical Center Scientists' Discovery Of Rare Gene Mutation ... BioNews Texas ... Development, UT Southwestern and Investigator, Howard Hughes Medical Institute, UT Southwestern; and Dr. Helen H. Hobbs, Professor, Department of Medicine Department of Molecular Genetics at the University of Texas Southwestern Medical Center in ... |
Uncategorized
Comments Off on UT Southwestern Medical Center Scientists’ Discovery Of Rare Gene Mutation … – BioNews Texas |
July 14th, 2013
Study cracks universal RNA code, suggests a new cause for autism – Phys.Org
By Dr. Matthew Watson
Study cracks universal RNA code, suggests a new cause for autism Phys.Org "This was a surprising finding, because we knew RBFOX1 controls gene expression, but had no idea it also stabilizes RNA," said Tim Hughes, a Professor in the Department of Molecular Genetics and the Donnelly Centre. "It's a good example of the ... |
Uncategorized
Comments Off on Study cracks universal RNA code, suggests a new cause for autism – Phys.Org |
July 14th, 2013
Common food supplement fights degenerative brain disorders – Heritage Florida Jewish News
By Dr. Matthew Watson
Common food supplement fights degenerative brain disorders Heritage Florida Jewish News A team headed by professor Gil Ast and Dr. Ron Bochner of Tel Aviv University's department of human molecular genetics decided to test whether the same chemical, which is naturally synthesized in the body and known to boost memory capability, could ... |
Uncategorized
Comments Off on Common food supplement fights degenerative brain disorders – Heritage Florida Jewish News |
July 14th, 2013
TV News Piece on Pay-for-Eggs Airs in Los Angeles, San Francisco
By Dr. Matthew Watson
yesterday picked up some mainstream media coverage, including a
two-minute, 24-second segment on two major television stations in Los
Angeles and San Francisco.
mainstream media has largely ignored the bill, with a couple of
exceptions. The piece is also exceptional because it appeared on TV
news, which reaches many more people than print media.
chief for KABC-TV in Los
Angeles, KGTV in
San Diego, KGO-TV in San
Francisco and KFSN-TV in Fresno, prepared the segment, which included on-camera interviews with both
supporters and opponents. The video appeared on KGO and KABC
and may well appear later on the other stations. It can be seen at
the end of this item.
Bonilla, D-Concord, would remove the ban in California on paying
women for their eggs for stem cell and other scientific research.
Women can already be paid for their eggs for fertility purposes.
another mainstream media outlet this morning, the San Diego U-T.
Writing in an op-ed column, Leah Campbell said she sold her eggs at
age 25 and has since become infertile as the result of problems her
doctors believe involved the process of providing the eggs.
“Six months (after providing the
eggs) my body began to fail me. I had always been a healthy and
active woman, but suddenly I was crippled by pain and unable to live
the life I had once enjoyed. I was soon diagnosed with stage IV
endometriosis, a disease my doctors now believe was pushed into
overdrive as a result of the potent hormones involved in my egg
donation protocols.”
“AB 926 may open the doors for
increased fertility research, but the potential costs for women’s
lives and health far outweigh any compensation that could ever be
offered.”
Source:Stem Cell Therapy
Comments Off on TV News Piece on Pay-for-Eggs Airs in Los Angeles, San Francisco |
July 14th, 2013
Shestack Resignation Letter: Heartfelt and Eloquent
By Dr. Matthew Watson
 |
| Jon Shestack(l) with J.T. Thomas, chairman of CIRM, at a 2012 board meeting California Stem Cell Report photo |
resigned this week as a director of the
California stem cell agency, was on board on Day One in December 2004
when the agency's work began with no offices, no desks, no chairs, no phones and
no ability to even write checks.
of his work in the autism community. He and his wife, Portia Iversen,
founded Cure Autism Now in 1995. A Hollywood film producer, Shestack
rattled cages at CIRM from time to time during his eight years of
service. And earlier this week, he wrote a heartfelt, eloquent
resignation letter, which he provided to the California Stem Cell
Report. The full text can be found below. Here are some excerpts.
“Over eight years there were moments
that were inspiring, some were contentious, and there was a bruising
number of meetings but through it all, the board was involved,
passionate and, will forever be for me, the gold standard when it
comes to integrity.
“The same goes double for the staff –
truly the most excellent, devoted, committed group of people I
have ever had the pleasure of working with.”
“When I started at CIRM, my sweet son
with autism was 12. Now he is 21. Over eight years our family has
learned more about how many are the challenges that await him and how
few the opportunities he has to look forward to. We have seen his
world get smaller and smaller. While my son is special to me. He is
not unique. There are thousands and thousands affected by mental
illness who need a better life.
“Sometimes feel that I have failed
these people, in particular those affected by autism or cerebral
palsy. Though CIRM ran first-rate workshops on these disorders, we
did not do all we could to follow up, put out disease-specific RFAs
and get in proposals that addressed the workshop recommendations. I
wish I had been more persuasive."
“In the movies, the third act is
where the hero takes stock of all the previous wins and losses, all
the hardships and lessons learned, and she puts all that knowledge
together in new, and surprising ways until victory is within reach!
As CIRM enters its third act, I hope it will do the same. I hope it
will challenge itself, always put the urgency of the mission
ahead of everything else and be willing to question the policies that
have been so successful in the past, and consider that new ones may
be needed for the future.
“And this is the future as I see it
for CIRM. We will have faith, but we will continue to earn our
miracles We will use our hearts and our minds to rip those miracles
out of the dreamy future and make them real today. We will seek out
the best scientists and encourage them to use all their wisdom, art
and discernment to bring us cures. And when we have done that, we
will do it again the next day. We will be optimistic, but not
satisfied. We will question authority, despise complacency and above
all love those among us in need of healing--this is the obligation
without end, whose reward is also without end.”
Source:Stem Cell Therapy
Comments Off on Shestack Resignation Letter: Heartfelt and Eloquent |
July 14th, 2013
Veto Campaign Launched on California Pay-For-Eggs Bill
By Dr. Matthew Watson
pay-for-eggs bill have kicked off a campaign to urge Gov. Jerry Brown to veto the industry-backed legislation.
Berkeley yesterday posted a pitch on its website urging readers to
contact the governor's office by email, fax, phone or letter. The
target is a bill that would remove the ban in California on paying
women for their eggs for stem cell and other scientific research.
Women can already be paid for their eggs for fertility purposes.
director of the center, wrote,
“If you agree that more research on
short- and long-term risks is needed before expanding the market for
women’s eggs, please act quickly. Contact Governor Brown and ask
him to veto AB926.”
Alliance for Humane Biology, another San Francisco Bay area
organization.
Bonilla, D-Concord, has literally been cloaked in motherhood/reproductive issues. The measure has easily swept through the legislature and is now on its
way to the governor. The bill is sponsored by the AssociationFew if any stem cell or other research
organizations have been heard from during hearings on the bill. (For
more information, see here, here and here.)
complained in past years about the lack of eggs for research,
declaring that women want to be paid.
compensation for eggs in research funded by the $3 billion California
stem cell agency. However, the agency on July 24 will consider providing exceptions for stem cell lines derived from eggs that
involve compensation for women.
Source:Stem Cell Therapy
Comments Off on Veto Campaign Launched on California Pay-For-Eggs Bill |
July 14th, 2013
Sacramento Mental Health Advocate Appointed to Stem Cell Agency Board
By Dr. Matthew Watson
 |
| Al Rowlett Turning Point photo |
Rowlett has been named to the governing board of the $3 billion
California stem cell agency, it was announced today.
the 29-member panel. Shestack had served on the board since 2004,
when the agency was created by the Proposition 71 ballot initiative.
the CIRM board by California Assembly Speaker John Perez, D-Los
Angeles. Rowlett will fill one of the 10 patient advocate slots on
the board. He will be only African-American on the panel. The board
had also included one African-American, Ted Love, from 2004 to April
2012, when Love resigned.
governmental service. He is in his second term as a member of the Elk
Grove school board, the fifth largest school district in California.
He has worked for Turning Point since 1981.
serves on several other boards including Child Abuse Prevention
Center, California Institute of Mental Health and is a commissioner
for the United States Psychiatric Rehabilitation Association
Certification Program. In 2007, Rowlett won the National Association
of Social Work- California and California State University – Heart
of Social Work Award and the Asian Pacific Community Counseling –
Inspirational Mental Health Leadership Award.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/C2aH568yoco/sacramento-mental-health-advocate.html
Stem Cell Therapy
Comments Off on Sacramento Mental Health Advocate Appointed to Stem Cell Agency Board |
July 14th, 2013
California Stem Cell Merger: Capricor and Niles Therapeutics
By Dr. Matthew Watson
benefiting from $27 million from the California stem cell agency,
this week announced that it is merging with Niles Therapeutic, Inc.,
of San Mateo.
 |
| Linda Marban Capricor photo |
for heart disease have been highlighted (see here and here) by the $3
billion state research agency, which is partially funding a clinical
trial for the firm. The firm sprang from work by Eduardo Marban of
Cedars-Sinai in Los Angeles, one of Capricor's founders. He received
$6.9 million for his early and current work. Capricor was awarded
$19.8 million more.
the publicly traded Niles announced on Monday that they were merging.
The new company will be known as Capricor Therapeutics, Inc., and will
be based in San Mateo.
with Capricor CEO Linda Marban as the new CEO.
two members from Niles and seven from Capricor, including its
executive chairman, Frank Litvack, who was an unsuccessful candidate for chairman of the stem cell agency board in 2011.
new company “should
have better access to capital, more potential for steady pipeline
development and more risk diversification."
press release said,
“Nile
will issue to Capricor stockholders shares of Nile common stock such
that Capricor stockholders will own approximately 90% of the combined
company's outstanding shares, and Nile stockholders will own
approximately 10%, calculated in each case on a fully-diluted basis
assuming the issuance of shares underlying options and warrants.
Options of Capricor will be assumed by Nile and become options to
acquire stock of Nile.”
"Capricor's
and Nile's product portfolios complement each other well, as our
therapies will address both the underlying causes and debilitating
effects of heart disease. Capricor's CDCs are allogeneic cardiac
derived stem cells that aim to attenuate and potentially improve
damage to the heart that can result in heart failure, while Nile's
cenderitide is intended to treat patients following hospital
discharge from an acute episode of heart failure."
recently. Its 52 week high was $0.20 and the 52-week low was $0.02.
Source:Stem Cell Therapy
Comments Off on California Stem Cell Merger: Capricor and Niles Therapeutics |
July 14th, 2013
Pay-for-Eggs Legislation: Strange Bedfellows and Existential Questions
By Dr. Matthew Watson
today generated a feature article that said the legislation has
“sparked an unusual lineup of partisans on both sides and resonates
far beyond” the Golden State.
Weekly, a news service specializing in California government and
political coverage, said,
“(C)omplicating the issue is
California’s role as a national leader in stem cell research, the
existential question of who or what constitutes a research subject,
and finally, the fact that compensation for fertility purposes is and
has been legal for years in California.”
(AB926) by Assemblywoman Susan Bonilla, D-Concord, that removes a ban
in California on paying women for eggs for scientific research.
Currently women can be paid in California for providing eggs for IVF.
The measure would not alter a ban on compensation for eggs in
research financed by the $3 billion California stem cell agency.
However, later this month, the agency will consider modifying its position somewhat.
is on its way to Gov. Jerry Brown. The industry association
sponsoring the bill expects the governor to sign it later this month
although the governor, as a general rule, does not make public
commitments on legislation.
and arguments on the bill and noted that it has received little
mainstream media attention.
 |
| Lisa Ikemoto UC Davis photo |
professor and bioethicist at UC Davis, on the sensitive nature of the
issue. Ikemoto said,
“On the fertility side, it’s
politically hard to touch because it’s all around family formation.
Nobody wants to restrict family formation. On the research side, when
the issue of payment for eggs came up, it was connected with human
embryonic stem cell research, and human embryonic stem cell research
was politicized from the outset.”
bedfellows opposing the bill. She said,
“Groups that fundamentally oppose
stem cell research such as the California Catholic Conference and
other pro-life groups are natural opponents of the bill, but they are
joined by a number of pro-choice groups who expressed concerns over
the limited research on the effects of egg donation on women’s
health.”
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/pskHpPceyco/pay-for-eggs-legislation-strange.html
Stem Cell Therapy
Comments Off on Pay-for-Eggs Legislation: Strange Bedfellows and Existential Questions |
July 14th, 2013
"Comfort News" for California’s Stem Cell Research Effort
By Dr. Matthew Watson
enjoyed a spate of good financial and scientific news this week from
the biotech industry as the research effort pushes on with its
mission of turning stem cells into cures.
scheduled to make its last grants in less than three years and, given
the glacial pace of medical research, needs all the help it can get
by then to bring a stem cell therapy close to the marketplace – the
promise it made to voters when the agency was created nine years ago.
not only steady scientific progress but also a rosy outlook for the
industry, which has languished in past years as major investors
shunned the field. This week, CIRM garnered good news on both fronts.
even touted it on the agency's research blog in an item by
Neil Littman, CIRM's business development officer. He said it all
helps to leverage CIRM investments and create a favorable investment climate. The good news included yesterday's announcement that
Viacyte, Inc., of San Diego, Ca., has come up with $10.6
million needed to match a $10.1 million, much-ballyhooed award from CIRM last fall. The Viacyte financing
includes important support from Big Pharma, in the form of Johnson &
Johnson. CIRM has pumped a total of $39.4 million into Viacyte.
Cellular Dynamics International, Inc., of Madison, Wisc., yesterday
announced its price on its upcoming stock offering to raise up to $53
million. Cellular Dynamics scored $16 million from the agency last
March.
better outlook for biotech in general. John Carroll, editor of Fierce
Biotech, this week noted that there were only 11 biotech stock offerings last
year. He wrote,
“In the last 6 months, though, the
industry has seen a tremendous rebound, with almost twice that number
of IPOs in half the time. And there's no sign that the great leap
into the public market is waning, with 10 more IPOs in the queue.”
piece by Peter Winter on Bioworld headlined “Bubbleology and Biotech's Bull Run.”
call the “everybody's-doing-it dance" or the “lemming
syndrome,” depending on your point of view. The reality is that
big investors and venture capitalists are timid souls and need the
comfort of companionship-in-risk as they fork over tens or hundreds
of millions of dollars on something that may not pay off for a decade
or more. No one wants to be the out-front pioneer who winds up with
financial arrows in his or her back. Being in a crowd provides an
illusion of safety.
about how markets and investors are fickle. A piece of bad news can
translate quickly into major reversals as Apple has learned over the
last year. Nonetheless, the folks at the stem cell agency have to be feeling good today.
Source:Stem Cell Therapy
Comments Off on "Comfort News" for California’s Stem Cell Research Effort |
July 14th, 2013
HIV Clinical Trial Hailed by California Stem Cell Agency
By Dr. Matthew Watson
California stem cell agency today scored what it called an “important
milestone” with the announcement of the start of a clinical trial
involving a therapy to help protect persons infected with HIV from
the effects of the virus.
trial is partially funded from a $20 million award from the stem cell
agency, which is known as CIRM, to researchers
at UCLA and Calimmune, a Tucson, Az.,
company. Calimmune's share of the award was $8.2 million.
Trounson, president of the $3 billion state agency, said in a
statement,
“CIRM
funding of this Phase l/ll trial is an important milestone for us.
One of our goals is to support research that moves the most promising
science out of the lab and into clinical trials in people. To be able
to do that with a disease as devastating as HIV/AIDS highlights the
importance of our funding and the potential impact it could have on
the health of people around the world.”
Thetrial was announced by Calimmune this morning. The company said,
first patient has begun treatment in a Phase I/II clinical trial
designed to determine whether a pioneering genetic medicine approach
can help to protect individuals infected with HIV from the effects of
the virus. The study, “Safety
Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1
Infection,”
utilizes a gene medicine called Cal-1, developed in the lab of Nobel
Laureate Dr. David
Baltimore and
by Calimmune.”
served on the CIRM board from 2004 until June 6, 2007. He resigned
from the board about
18 months before the application process began for the grant round
that ultimately funded Calimmune, a company he helped to found. He is currently chairman of the Calimmune board.
for comment, Jeff Sheehy, a member of the CIRM governing
board and communications director for AIDS research at UC San
Francisco, said,
"This
trial will hopefully offer several important insights into the safety
and feasibility of genetically modifying blood forming stem cells in
an HIV patient as a potential therapy. We are very early in
this research, and with this Phase I trial's goal of establishing
safety and the risks involved, I applaud the courage and altruism
demonstrated by the patients who are willing to participate in this
study."
press release said
the principal investigators on the clinical trial are Ron
Mitsayasu of
UCLA and Jacob
P. Lalezari of Quest
Clinical Research of
San Francisco. Quest is currently soliciting patients for the
clinical trial as well as UCLA. (Persons interested in participating
in the trial can find email contacts at
this website.
Twelve are needed.)
principal investigators on the CIRM award are Irvin Chen of
UCLA and Geoff Symonds of Calimmune.
Source:Stem Cell Therapy
Comments Off on HIV Clinical Trial Hailed by California Stem Cell Agency |
July 14th, 2013
Eggs and Cash: Stem Cell Agency Considering Easing Restrictions on Stem Cell Lines Derived Using Payments
By Dr. Matthew Watson
moving to remove an absolute ban on use of stem cell lines derived
from eggs from women who have been paid to provide them.
is headed for Gov. Jerry Brown's desk that would permit payments for
eggs to be used in research that is not funded by the agency. The measure (AB926) would not alter the separate ban on egg payments
involving research funded by the $3 billion stem cell agency.
approve the use of stem cell lines derived as a result of payment to
women. Board action would be based on whether stem cell lines would
“advance CIRM's mission” and would follow a staff evaluation
involving scientific and ethical issues.
researchers around the country have reported that they are not able
to obtain sufficient eggs without payment. And earlier this year,
paid egg providers were used in research in Oregon that cloned human stem cells, a feat that researchers have struggled with for years.
Oregon research has “generated scientific interest among CIRM
grantees and the desire to utilize derived SCNT lines. CIRM’s
current policy prohibits the use of the (Oregon) SCNT lines because
oocyte donors were financially compensated. CIRM requests the Medical
and Ethical Standards Working Group (SWG) revaluate this prohibition
with regard to CIRM grantees ability to utilize the resulting lines
in light of recent scientific and policy developments.”
Report queried the agency concerning earlier, sketchy information onthe CIRM blog about a possible change in its compensation rules. We
asked whether the agency was considering “sidestepping” the ban
on compensation. Kevin McCormack, a CIRM spokesman, said, “No, not
at all.” He said it would be premature to elaborate until a firm
proposal was ready.
July 24 said,
“Proposition 71’s 'prohibition on
compensation' compels the ICOC(the agency's governing board) to adopt
standards 'prohibiting compensation to research donors.' This
requirement has been consistently interpreted to prohibit the use of
CIRM funds to financially compensate oocyte (or other cell or tissue)
donors. In 2006, this interpretation was extended to exclude from
use, in CIRM-funded research, any stem cell line where research
donors were financially compensated, even if the derivation was done
without the use of CIRM funds. Proposition 71, however, does not
compel the ICOC (the agency's governing board) to prohibit the use of
stem cell lines where financial compensation is provided to the
oocyte donors, provided that CIRM funds are not used to compensate
the donors or derive the lines.”
Francisco. No remote teleconference locations have been announced. If approved, the changes would likely be considered July 25 by the full agency board.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/BF3kpSRnKXQ/eggs-and-cash-stem-cell-agency.html
Stem Cell Therapy
Comments Off on Eggs and Cash: Stem Cell Agency Considering Easing Restrictions on Stem Cell Lines Derived Using Payments |
July 14th, 2013
California Legislation Removing Ban on Payments for Eggs for Research Heads to Governor
By Dr. Matthew Watson
California to be paid for their eggs for scientific research is on
its way to Gov. Jerry Brown following final legislative approval last
week.
fertility industry organization, expect the governor later this month
to sign the measure, which would go into effect next year.
Susan Bonilla, D-Concord, would repeal a ban on payments to women who
provide eggs for scientific research. However, the measure would not
affect the ban on payments to egg providers in research funded by the
$3 billion California stem cell agency. That ban is covered by a
separate legal provision. Stem cell researchers around the country have complained that they they cannot get eggs without payment.
providing eggs for reproductive purposes. According to a legislative analysis, payments can run as high as $50,000 for women with special
characteristics but average around $9,000 for each session, which can
generate more than one egg.
American Society for Reproductive Medicine of Alabama, whose members
represent a wide swath of the $5 billion-a-year fertility business.
The measure would open new business avenues for the industry.
research and would encourage more research into reproductive health issues.
egg production procedures has not been well-established including
their long-term impact. They also argue that allowing payment would
lead to exploitation of poor and minority women.
legislative approval on July 1 when the Senate passed it on a 24-9
vote.
Source:Stem Cell Therapy
Comments Off on California Legislation Removing Ban on Payments for Eggs for Research Heads to Governor |
July 14th, 2013
Questions you should ask to doctor for Alzheimer disease
By Dr. Matthew Watson
Alzheimer’s Disease is a critical health condition that cannot be defined in a specific way.It is a very common form of Dementia. Dementia in itself is not a disease. Rather, it is a group of symptoms that start occurring due to occurrence of some other disease or medical condition.Person suffering from Alzheimer’s Disease can face difficulty in remembering even the most recently happened events. This is the initial stage. The disease can lead to death of a person too! The disease starts to occur in people who have crossed 65 years of age or more. Those who get diagnosed with this difficult disease, a good doctor needs to be consulted at the earliest. There are certain questions that need to be placed before the doctor related to the disease. Some of the most important questions are listed below:
What is the usual course of the Alzheimer’s disease?
Life long.
What type of new treatments are available?
Since it is not a disease, there is no particular treatment available. However, some medicines are available but that too works at the early stages.
Are the drugs used to treat the AD symptoms effective?
Yes, at times and mostly during the early stages.
Does these drugs have any sort of side effects?
At time, yes. It can cause poor eyesight problem, gaining weight, as well itching problems.
Does the AD affects a person for the remaining part of his/her living days?
Yes, definitely.
What is the total time period for a person to act in a very normal way post Alzheimer’s diagnosis?
The first and middle stages are still OK with the patients. Although slight changes start taking place but still the behavior doesn’t get completely out of the mark. But, once the patient reaches advanced stage, scenarios tend to become more complicated.
Can a patient of Alzheimer’s Disease be a threat to other or themselves?
The Patient can be a real threat to him/herself. At advanced stage, the patient can even forget her/his own address, name, etc. Scenarios can get real complicated when the patient fails to identify his/her relatives, family members and friends.
Is home or nursing home the best place to take care of the person suffering from AD?
No, there is no such a thing. A lonely person with no one to take care of can stay best in a nursing home. But a person with good family and friends can easily stay in the home. Alzheimer’s is a not a disease but a syndrome that can be as deadly as any other disease. But, there is no specific treatment for it. So, there is no need to spend unnecessary money booking a bed in the nursing home.
What are the necessary precautions to take in order to make the home surroundings safe for someone who has been diagnosed with Alzheimer’s?
A clean surrounding can definitely help. The person suffering from AD should be kept stress free. The patient should have more interaction with family members and friends. However, by no means the patient should be made excited or furious. It can provide extra stress on the brain. This can cause some negative repercussions.
What are the best available support and services are available in the local area related to Alzheimer’s disease?
This is a very important question to ask the doctor. Remember, if local medicinal help can be availed, then much of worries are eliminated.
Is Alzheimer’s considered a hereditary disease?
Yes, definitely. But it is only a small part of the bigger process. AD can develop due to several factors, most important being strong stress.
Source:
http://www.biotechblog.org/entry/questions-doctor-alzheimer-disease/
Uncategorized
Comments Off on Questions you should ask to doctor for Alzheimer disease |
July 7th, 2013
Farmers want Rajasthan govt to oppose biotechnology bill – Times of India
By Dr. Matthew Watson
Farmers want Rajasthan govt to oppose biotechnology bill Times of India JAIPUR: Seeking an extension of the July 10 deadline for public feedback on the Biotechnology Regulatory Authority of India (BRAI) Bill 2013, farmers and NGOs have requested the state government to send its objections to the bill in the interests of ... |
Uncategorized
Comments Off on Farmers want Rajasthan govt to oppose biotechnology bill – Times of India |
July 7th, 2013
Cattle Flatulence Doesn’t Stink With Biotechnology: Farmers Could Improve Air … – Science Daily (press release)
By Dr. Matthew Watson
Cattle Flatulence Doesn't Stink With Biotechnology: Farmers Could Improve Air ... Science Daily (press release) Researchers measured gas output by placing finishing steers in a special corral that traps emissions. Each treatment group was tested four times to ensure accurate results. The researchers also tested a dairy biotechnology called rBST. This ... Cattle flatulence doesn't stink with biotechnologyScience Codex |
Uncategorized
Comments Off on Cattle Flatulence Doesn’t Stink With Biotechnology: Farmers Could Improve Air … – Science Daily (press release) |
July 7th, 2013
Penny Stocks Alert – Medora Corp(OTCMKTS:XUII), Generex Biotechnology … – SBWire (press release)
By Dr. Matthew Watson
Penny Stocks Alert - Medora Corp(OTCMKTS:XUII), Generex Biotechnology ... SBWire (press release) Generex Biotechnology Corporation(OTCMKTS:GNBT) stock is at $0.0395, up +12.54 percent from its previous close of $0.0351. Its today's volume is 10.07 million shares in comparison to its usual trading volume of 4.73 million shares. The stock opened the ... Penny Stocks Buzz: Imageware Systems (OTCMKTS:IWSY), Generex ...Techsonian Today's High Gainers: Xumanii (OTCMKTS:XUII), Generex Biotechnology ...NIS |
Uncategorized
Comments Off on Penny Stocks Alert – Medora Corp(OTCMKTS:XUII), Generex Biotechnology … – SBWire (press release) |
July 7th, 2013
India, Vietnam to begin collaborative multi-disciplinary research in biotechnology – pharmabiz.com
By Dr. Matthew Watson
India, Vietnam to begin collaborative multi-disciplinary research in biotechnology pharmabiz.com To build on the combined strengths of academic research groups within India and the Socialist Republic of Vietnam, both the countries will soon begin collaborative multi-disciplinary research in the areas biotechnology including medical biotechnology ... |
Uncategorized
Comments Off on India, Vietnam to begin collaborative multi-disciplinary research in biotechnology – pharmabiz.com |
July 7th, 2013
Monday Sector Leaders: Biotechnology Stocks – Forbes
By Dr. Matthew Watson
 Bloomberg | Monday Sector Leaders: Biotechnology Stocks Forbes In trading on Monday, biotechnology shares were relative leaders, up on the day by about 2.7% as a group, led by Onyx Pharmaceuticals (ONXX), trading higher by about 50.6% and Ariad Pharmaceuticals (ARIA), trading higher by about 12.6% on Monday. Biotechnology company Onyx rejects Amgen's $10 -bn takeover biddomain-B Onyx Rejects Amgen's Takeover Bid, Then Places Itself on the MarketNew York Times ETFs For an Onyx Takeover BattleFox Business Bloomberg all 215 news articles » |
Uncategorized
Comments Off on Monday Sector Leaders: Biotechnology Stocks – Forbes |
July 7th, 2013
Biotechnology Can Help Lessen The Effects Of Cow Farts – RedOrbit
By Dr. Matthew Watson
 RedOrbit | Biotechnology Can Help Lessen The Effects Of Cow Farts RedOrbit The research team also tested a dairy biotechnology called rBST – a synthetic version of a cattle hormone that does not affect humans. Many dairy producers use rBST to help the cows produce more milk. The team injected one group of cattle with rBST and ... |
Uncategorized
Comments Off on Biotechnology Can Help Lessen The Effects Of Cow Farts – RedOrbit |
July 7th, 2013